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Abstract
Background: Efficacy of high-dose vitamin A (VA) in children suffering from severe acute malnutrition (SAM) has recently
been questioned. This study compared the efficacy of a single high-dose (200,000 IU) in addition to daily low-dose (5000 IU)
VA in the management of children suffering from SAM with diarrhea and/or acute lower respiratory tract infection (ALRI).
Methods: In a randomized, double-blind, controlled clinical trial in icddr,b, Bangladesh during 2005–07, children aged 6–59
months with weight-for-height ,23 Z-score and/or bipedal edema (SAM) received either a high-dose VA or placebo on
admission day. Both the groups received 5,000 IU/day VA in a multivitamins drop for 15 days and other standard treatment
which is similar to WHO guidelines.
Results: A total 260 children (130 in each group) were enrolled. All had diarrhea, 54% had concomitant ALRI, 50% had
edema, 48.5% were girl with a mean6SD age of 16610 months. None had clinical signs of VA deficiency. Mean6SD
baseline serum retinol was 13.1569.28 mg/dl, retinol binding protein was 1.2760.95 mg/dl, and pre-albumin was
7.9763.96 mg/dl. Median (inter quartile range) of C-reactive protein was 7.8 (2.1, 22.2) mg/L. Children of the two groups did
not differ in any baseline characteristic. Over the 15 days treatment period resolution of diarrhea, ALRI, edema,
anthropometric changes, and biochemical indicators of VA were similar between the groups. The high-dose VA
supplementation in children with SAM did not show any adverse event.
Conclusions: Efficacy of daily low-dose VA compared to an additional single high-dose was not observed to be better in the
management of children suffering from SAM with other acute illnesses. A single high-dose VA may be given especially
where the children with SAM may leave the hospital/treatment center early.
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Introduction
Diarrheal diseases, acute lower respiratory tract infection
(ALRI), malnutrition, and vitamin A (VA) deficiency are common
health problems in developing countries including Bangladesh. VA
supplementation has proved effective in reducing childhood
mortality in VA-deficient communities [1]. The World Health
Organization (WHO) recommends giving high-doses of VA
(200,000 IU for children more than one year old and half the
dose to those aged 6–12 months) to children who suffer from
severe protein-energy malnutrition (PEM) [2,3], measles, pro-
longed diarrhea, and to VA deficient populations [4,5]. There are
quite a good number of studies those reflect positive effect of VA
both in preventive as well as curative perspectives. However, some
studies [6–11] that have examined the effect of high-dose VA
supplementation on diarrhea and respiratory infections in children
showed no beneficial effect, and in few studies, high-dose VA was
associated with adverse effects, particularly in children with
respiratory infection [9,10,12–15]. These varied responses of both
beneficial and adverse effects are not yet fully understood. It has
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well-nourished children particularly who had better VA status, but
the role of nutritional status is difficult to estimate because most of
the studies were done in non-severely malnourished or non SAM
children.
Two clinical trials, performed by Donnen et al in Congolese [9]
and Senegalese [16] children tested the effect of low-dose VA on
all-cause morbidity. In the first study [9], effects of daily low-dose
(5000 IU) and single high-dose (200,000 IU) VA were compared
with a placebo. The duration and incidence of ALRIs were not
found influenced by VA supplementation, regardless of the dose.
However, ALRI on admission and in the course of hospitalization
was rare in this sample of children and this fact could have masked
some real effect. Neither a high-dose nor low-dose of VA had any
significant effect on the duration of diarrhea and nosocomial
diarrheaalso in the second study [16], which showed that
nosocomial respiratory disease was lower in the low-dose group
However, the children in both the studies were not exclusively with
severely malnourished: mean weight-for-height (WHZ) of the
studied children was -1.25 to -1.34 [9], and 44.7% to 48.6% had
,22 WHZ [16]; as well as few had edema: 18.2% to 21.3% [9]
and 4.0% to 5.9% [16]. Interpretation of the studies [9,16] in
relation to the existing guidelines on VA supplementation in
children with SAM was considered difficult, and this issue was
flagged for further research in a meeting convened by WHO in
September 2004 [17].
The purpose of the present study was to assess the efficacy of
daily low-dose (5000 IU) versus an additional single high-dose
(200,000 IU) on the recovery from diarrhea and ALRI including
nosocomial infections in children with severe acute malnutrition
(SAM).
Methods
Setting and Study Design
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. The study was conducted at the Dhaka Hospital of
icddr,b which provides treatment to around 110,000 diarrheal
patients with or without associated complications each year. The
hospital is located in Dhaka, the capital city of Bangladesh with a
population of about 15 million. The vast majority of the patients
come from the poor socio-economic backgrounds from urban and
peri-urban Dhaka, and about 6,000 of them, mostly under-five
children, require hospitalization for five or more days in the longer
stay wardfor complications of diarrhea or presence of other infectious
diseases, particularly ALRI, sepsis, and severe malnutrition.
This was a randomized, placebo-controlled double blind clinical
trial conducted between June 2005 and May 2007. This study was
approved by Research Review Committee and Ethical Review
Committee of icddr,b. A written informed consent was obtained
from the respective parents/guardians of the each participating
children.
Subject Recruitment
Hospitalized children aged 6–59 months of either sex were
invited to be enrolled into the study if they fulfilled the following
inclusion criteria: WHZ,23 and/or bi-pedal nutritional edema
i.e. they were suffering from SAM, and consent obtained from the
guardian or parents. Children were excluded if they had clinically
apparent congenital disorders that might affect growth, other
acute or chronic diseases requiring continued hospitalization,
active sign of VA deficiency or history of night blindness, active
measles or history of measles with in the previous 8 weeks, received
high-dose VA supplementation in the previous 3 months, and lack
of a fixed address (to avoid difficulties in tracing for follow-up
examinations).
Randomization and Dosing
Eligible children were randomly assigned to either a high-dose
or placebo using a computer-generated block randomization
scheme with a block length of ten. Boh the groups received daily
low-dose VA. Randomization was done by a researcher not
involved in the study. A pharmaceutical company (Drug
International limited, Bangladesh) prepared and supplied the
high-dose VA capsules and placebo for the study. The placebo
preparation and active drug were similar in consistency, color and
taste. A person not affiliated with the study did the identification
codes for the individual wrapped bottles of capsules. The bottles
were unwrapped just before administration.
The research assistant screened the children/patients and then
one of the investigators assessed the patients and they together
took the consent to enroll the children in the study from the
parents. Trained study personnel administered the study inter-
ventions (which were randomly pre-assigned to the children). The
assignment of patients in the treatment groups were concealed to
both the investigators and patients by enclosing the assignment
card containing the code number for each patient into an opaque,
sealed envelope which was opened only at the time of allocating
patients to the study. At the start of trial, the high-dose group
received an oral dose of 200,000 IU VA (100,000 IU VA if
age,12 months) and the other (low-dose) group received placebo.
Both the groups from the very first day received 5,000 IU/day VA
in the form of multivitamin drops for 15 days. The date and time
of administration was recorded. Each study day was defined as the
24 hours that started with the administration of the study drugs.
Patient Management
The children were managed in two phases: (a) an initial
stabilization phase and (b) the nutrition rehabilitation phase
following the hospital’s guidelines [18], which is very similar to the
WHO guidelines [2,3]. The initial treatment in the stabilization/
acute phase began with admission to the hospital and lasted until
the child’s condition was stable and appetite had returned, which
usually took 3–7 days. The principal tasks during initial treatment
included treatment and prevention of hypoglycemia, hypothermia,
dehydration, electrolyte imbalance, shock, frequent feeding with a
milk-based diet, and treatment of infections and other problems.
This phase of treatment ended when the child got back a normal
appetite. Nutritional rehabilitation was done as per the standard
practice of the hospital. This included giving rice-lentil-based foods
[19] (khichuri: a cooked mix of rice, lentils, vegetables and soybean
oil and halwa: a sweet thick porridge made from cereal powder and
lentils) and a high energy milk-based diet which was gradually
tapered in amount. Breastfeeding was encouraged and continued
between formula feeds. Iron, which was not given in the initial
phase, was started during the nutrition rehabilitation phase at a
dose of 3 mg of elemental iron/kg per day. The other tasks during
nutritional rehabilitation phase were: encouraging the child to eat
the offered food stimulating emotional and physical development,
and preparing the mother or caretaker to continue to look after the
child at home following discharge. A trained health worker
counseled the mother/caregiver in the following areas: (a)
breastfeeding and preparation of nutritious solid food with
available food ingredients; (b) management of fever and diarrhea
at home; (c) danger signs of common illnesses; (d) benefits of
immunization. The discharge criteria were: absence of sign of
infection, general condition had improved, and the children had
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nutritional rehabilitation unit for 15 days (which ever was longer).
Data Collection
An interviewer-administered pretested questionnaire was used
to collect information on socioeconomic and dietary data,
obtained from the mothers or guardians after the children had
entered the trial. During hospitalization, one of the investigators
assessed the study children at least once daily and recorded
morbidity including weight data on a pre-designed and pre-tested
case report form (CRF). Length (for less than 2 years old), height
(for 2 to 5 years old), mid-upper-arm-circumference (MUAC) and
occipito-frontal (head) circumference were measured at base line,
on day 7 and on day 15. Morbidity data including number and
consistency of stool, vomiting, fever (rectal temperature) were
measured thrice daily in every 8 hours interval, and all other
symptoms over the preceding 24 hours. Each child was weighed
every morning, without clothes to the nearest 10 gm using an
electronic weighing scale (model 6810: Seca Corporation,
Columbia, MD), which was calibrated daily. Length and height
were measured with a locally made standard length/height board
to the nearest 0.1 centimeter. MUAC (measured half way between
the elbow and the shoulder of the left arm) and head
circumference were measured with a nonexpanding plastic tape
and recorded to the nearest 01 mm. The results are reported in
relation to the new (2006) WHO growth standards and expressed
as WHZ, weight-for-age (WAZ) and height-for-age (HAZ) z scores.
Blood samples were taken from anticubital venipuncture for
measurement of electrolytes, creatinine, complete blood count,
total protein, albumin, retinol, retinol binding protein (RBP),
glucose, pre-albumin and C-reactive protein (CRP) on the
admission day before the administration of high-dose VA or
placebo. Routine and microscopic examinations of stool and urine
and ELISA of stool sample (to detect Rota virus), x-ray chest, pulse
oximetry and other tests including blood culture were done as the
patient’s condition demanded. Serum retinol and RBP were again
measured on study days 3 and 15.
Laboratory Procedures
Serum retinol was measured by high-pressure liquid chroma-
tography, a method adapted from that of Vanderpas and
Vertongen [20]. RBP was measured with a single-radial immune
diffusion technique using commercially available plates (The
Binding site, Birmingham, United Kingdom). Ring diameters (in
mm) were read with an electronic single-radial immune diffusion
plate reader 72 hours after inoculation of serum sample. For each
plate, 3 wells were used for standards of different concentrations
and 1 for quality control [21]. Other laboratory measures/assays
were done with standard procedures.
Outcome Variables and Definitions
The primary outcome measures were clinical success- defined as
cessation of diarrhea and improvement of ALRI (no temperature,
fast breathing, and rales on chest auscultation) within 48 hours of
study drug administration. The secondary outcome variables were
any adverse event or clinical features of VA toxicity (bulging
fontanel, headache, vomiting, seizure, change in mental condi-
tion), changes serum retinol and RBP levels, duration of resolution
of diarrhea, ALRI, edema, dermatosis, and other illness (if any),
changes in weight and length/height, nosocomial morbidities, and
mortality. Diarrhea was defined as passage of 3 or more watery or
semi liquid stools in a 24 hours period. The number of passage of
stools per 8 hours was recorded. An episode of ALRI was defined
as presence of at least 3 of the following i) cough, ii) fever, iii) rales,
iv) increased age-specific respiratory rates (.50 breaths and .40
breaths per minute in 6 to 11 months and 12 to 59 months old
group of children respectively) and v) chest x-ray findings
suggestive of pneumonia. An episode was considered elapsed
when there was 48 hours without any signs or symptoms of that
specific illness. An episode was considered new or a nosocomial
infection if it was preceded by an interval of 48 hours without
clinical features of that illness or if an infection newly appeared
48 hours after hospitalization.
Sample Size
In the Dhaka Hospital of icddr,b about 60% of the severely
malnourished children has cessation of diarrheal illness and
improvement of ALRI by 48 hours (unpublished data, ICDDR,B,
2005). Sample size estimation per group was done considering the
above mentioned two primary outcome variables. Considering
80% power (1-beta) and 0.05 significance level (type I error) and
,12% dropout rate, 130 children in each group would be able to
detect 17% or more difference in primary outcome variables
between the groups, and we enrolled a total of 260 children with
severe acute malnutrition in the two treatment groups.
Data Quality Control, Processing and Analysis
Strict data quality control was maintained throughout the trial.
Each case record form was reviewed, first by a research assistant
and then by the principle or co-principle investigator before being
handed over for data entry. Data were entered into a computer by
research assistant, and 10% of the entered data was checked by
one of the investigators. In addition, data were printed out
periodically for visual checks. Data were entered and analyzed
using SPSS for Windows (version 11.5; SPSS Inc., Chicago, IL,
USA). For normally distributed continuous variables, means were
compared using unpaired t-tests after checking the equality of
variance (Levene’s test). For non-normally distributed continuous
variables, the Mann-Whitney test was performed. Differences in
proportions were compared by the Chi-square test or Fisher’s
exact test if the expected number in any cell was ,5. A probability
of less than 0.05 was considered statistically significant. Time taken
to resolution of diarrhea, ALRI, edema and other illnesses were
compared between the groups by survival analysis. Logistic
regression was used to analyze incidence of nosocomial morbid-
ities, where in addition to treatment groups, admission retinol and
CRP levels, and edema and stunting status were included in the
model. All these variables were transformed into dummies and
were coded as either 0 (to indicate the reference category) or 1 (to
indicate the category at risk). Adjusted odds ratios and their 95%
confidence intervals were derived from the final logistic model.
Results
We assessed 743 children and 483 were excluded and the
remaining 260 children were randomized (Figure 1). Of them
48.5% were girls, 50% had edema, 71% were stunted (length or
height-for-age ,22 Z score), all had diarrhea, 54% had
concomitant ALRI and none had clinical signs of VA deficiency.
Their mean 6 SD baseline age was 16.269.9 months, serum
retinol was 13.1569.28 mg/dl, RBP was 1.2760.95 mg/dl, and
pre-albumin was 7.9763.96 mg/dl. Median (inter quartile range)
of CRP was 7.8 (2.1, 22.2) mg/L, and 45% had $10 mg/L. Of
the enrolled children 42% were VA deficient (serum retinol
,10 mg/dl), 39% had low VA (serum retinol between 10–20 mg/
dl), and only 19% had .20 mg/dl serum retinol (dectected after
enrollment in admission blood sample). Children of the two groups
did not differ at baseline in any of the nutritional, demographic,
High-Dose vs. Low-Dose Vitamin A in SAM
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33112socio-economic, and illnesses/admission morbidities (Table 1).
Over the first 48 hours percent of children who had resolution of
watery diarrhea, invasive diarrhea and ALRI (primary outcome
variables), and over total 15 days treatment period time taken for
cure/resolution of admission morbidities were similar between the
groups (Table 2), as well as between the edematous and non-
edematous children, whose baseline serum retinol and other
biochemical characteristics were also similar (data not shown).
Survival analysis also revealed no difference in resolution times
of different morbidities between the two treatment groups (data
not shown). Similarly over the first 48 hours and 15 days treat-
ment period changes in serum retinol, RBP were similar between
the groups (Table 3). Table 4 shows that changes of different
anthropometric measures were comparable between the high-and
low-dose VA treatment groups. In further exploratory analyses by
logistic regression, considering the treatment groups, initial retinol
and CRP levels, and admission edema and stunting status in the
model, it was found that incidence of nosocomial cough was 39%
less likely in high-dose VA group, adjusted (a) OR: 0.61, P=0.056,
and nosocomial ALRI was more in stunted children, aOR: 2.96,
P=0.002 (Table 5).
The number (%) of children left against medical advice before
completing the minimum 15 days treatment were 24 (19%) and 26
(20%) in high- and low-dose group respectively (figure 1). No
significant characteristic was found which could predict or help to
identify them from the children who completed the full study
periods. A total three children died, and all received high-dose VA,
but all were critically ill and had sepsis/septicemia. The first one
was a 13 months old girl with marasmic kwashiorkor, diarrhea
suppurative otitis media, sepsis, thrush and hypokalemia. The
second one was a 15 months old boy with severe wasting,
Salmonella group B enteritis with thrush and hypokalemia, and
the third one was a boy with marasmic kwashiorkor, diarrhea,
Klebsiella septicemia, dermatosis and hypokalemia. The mean
6SD serum retinol of the children who died was 11.9067.76 mg/
dl, and the deaths were not considered to be related to VA doses.
Discussion
This randomized, double-blind, placebo-controlled clinical trial
showed that the efficacy of low-dose VA supplementation was not
found to be better compared to the current practice of an initial
high-dose VA supplementation in reducing morbidity in Bangla-
deshi children with severe acute malnutrition (SAM) suffering from
diarrhea and/or ALRI, who were invariably VA deficient. The
major strengths of our trial were the rigorous study design and the
careful standardization of the clinical assessments. Randomization
and the double-blind design minimized the possibility of
confounding or differential misclassification. To our knowledge,
this was the first clinical trial to compare the effect of daily low-
dose, and additional high-dose VA supplementation on all major
and common morbidities in exclusively SAM children.
Figure 1. Study profile.
doi:10.1371/journal.pone.0033112.g001
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100,000 IU for 6–11 months old) VA is routinely supplemented to
under-five children every 6 months. In severely malnourished
children, nutrient deficiencies including that of protein, fat and
zinc could be limiting factors for the absorption and utilization of
the lipid-soluble vitamin [22,23]. A significant proportion of
supplemented VA may be excreted in faces and urine, and urinary
excretion is substantially increased in acute infections including
diarrhea that malnourished children frequently suffer from. It is
estimated that malnourished children lose 0.1 mmol (97 IU) of
retinol/day through urine during acute illness [21]. Children with
protein deficiency and edema, reduced their RBP synthesis [24],
Table 1. Baseline characteristics of children by treatment group.
High Dose Vitamin A Group
(N=130)
Low Dose Vitamin A Group
(N=130)
Age (mo): mean 6 SD 15.768.9 16.8610.9
Female 66 (51) 60 (46)
Predominant breast feeding up to first 6 months 84 (65) 96 (74)
Length: mean 6 SD 69.766.8 70.368.7
Length or height-for-age Z score*: mean 6 SD 22.7261.27 22.7461.24
Among non edematous children
Weight (kg): mean 6 SD 6.4061.34 6.8461.64
Weight-for-age Z score*: mean 6 SD 24.1660.77 24.0860.77
Weight-for-length or height Z score*: mean 6 SD 23.3260.53 23.3060.32
Children admitted with edema 66 (51) 64 (49)
MUAC
{ (mm): mean 6 SD 111.2610.7 111.6611.3
Head circumference (cm): mean 6 SD 42.162.2) 42.062.6
BCG
{ 120 (92) 117 (90)
Diphtheria, tetanus, pertussis and oral polio
(3
rd dose completed) 122 (94) 115 (88)
Measles 54 (59) 50 (56)
Income (taka per month) (1 US $=65 taka)
.10,000 2 (1.5) (0)
3,000–10,000 27 (20.8) 29 (22.3)
,3,000 101 (77.7) 101 (77.7)
Admitted with acute watery diarrhea 117 (90) 118 (91)
Admitted with invasive diarrhea 13 (10.0) 12 (9)
Admitted with fever 72 (55) 65 (50)
Admitted with cough 73 (56) 66 (51)
Admitted with pneumonia/ALRI1 74 (57) 67 (52)
Admitted with skin change/dermatosis 16 (12) 14 (11)
Serum retinol (mg/dl): mean 6 SD 13.369.1 13.069.5
,10 57 (44) 53 (41)
10–20 46 (35) 54 (41)
.20 27 (21) 23 (18)
RBP" (mg/dl): mean 6 SD 1.2660.94 1.2960.95
CRP
I (mg/L): median (inter quartile range) 9.7 (2.4, 23.4) 7.5 (1.9, 20.2)
Pre-albumin (mg/dl): mean 6 SD 7.6463.95 8.3163.95
Hematocrit (%): mean 6 SD 32.763.8 32.764.5
Serum total protein (g/L): mean 6 SD 67.1610.4 67.7611.6
Serum albumin (g/L): mean 6 SD 37.667.0 38.067.4
Data are n (%) unless otherwise indicated.
*WHO new (2006) growth standard;
{MUAC: Mid upper arm circumference;
{BCG: Bacille Calmette Guerin.
1ALRI: Acute lower respiratory tract infection;
"RBP: Retinol binding protein;
ICRP: C-reactive protein.
No significant difference is observed for any variable between the groups.
doi:10.1371/journal.pone.0033112.t001
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to the target organs and tissues. Acute infections are also associated
with acute phase response and a transient decrease in serum
retinol level [25]. This is due to reduced transcription of messenger
RNA for RBP, resulting in decreased release of RBP from the liver
into the blood [26,27]. It is likely that liver utilizes all of its
available resources for rapid synthesis of proteins that are required
for the host defense in acute infection, thereby limiting the
synthesis of RBP.
It seems unlikely that the high-dose VA could have induced
adverse effects in this malnourished and VA deficient children of
our study, because most of the children were VA deficient on the
basis of their serum retinol concentrations (only 19% had an
admission serum retinol level .20 mg/dl), with a mean 6SD
Table 2. Resolution of morbidities by treatment group.
High Dose Vitamin A Group Low Dose Vitamin A Group P Value
Resolution/improvement by 48 hours: n (%) [primary outcome variables]
Resolution of acute watery diarrhea 51 (44) [117] 52 (44) [118] 0.314
Resolution of dysentery 7 (54) [13] 8 (67) [12] 0.790
Improvement of ALRI*
Cough 42 (58) [73] 35 (53) [66] 0.723
Fever 52 (72) [72] 48 (74) [65] 0.445
Rales 7 (44) [16] 6 (50) [12] 0.541
Duration of morbidities: mean 6 SD [primary outcome variables]
Acute watery diarrhea (hours) 73.9642.3 64.6640.8 0.071
Invasive diarrhea (hours) 97.8666.9 65.5629.5 0.360
Cough (day) 3.1562.56 2.8561.92 0.924
Fever (day) 2.0061.51 1.4860.98 0.288
Rales on chest auscultation (day) 4.6964.64 3.8661.95 0.635
Edema (day) 7.1164.08 7.5863.33 0.199
Skin change (day) 4.8062.11 4.1862.79 0.304
[n]: number of subject for that specific variable.
*ALRI: Acute lower respiratory tract infection.
doi:10.1371/journal.pone.0033112.t002
Table 3. Changes of serum retinol and retinol binding protein (RBP) over time by treatment group.
High Dose Vitamin A Group
(N=127)
Low Dose Vitamin A Group
(N=126) P Value
S. Retinol (mg/dl) on day 3: mean 6 SD 24.1611.4 23.7611.4
,10 10 (7.9) 15 (11.9)
10–20 39 (30.7) 30 (23.8)
.20 78 (61.4) 81 (64.3) 0.822
Difference (day 3 - baseline) of S. Retinol (mg/dl) after 48 hours: mean 6 SD 10.8611.5 10.8611.7
median (inter quartile range) 9.8 (4.5, 16.5) 9.9 (4.7, 5.7) 0.958
RBP* (mg/dl) on day 3: mean 6 SD 2.3061.12 2.2861.13 0.926
Difference (day 3 - baseline) of RBP (mg/dl) after 48 hours: mean 6 SD 1.0461.16 1.0061.18
median (inter quartile range) 0.92 (0.24, 1.71) 1.01 (0.21, 1.58) 0.904
(N=103) (N=104)
S. Retinol (mg/dl) on day 15: mean 6 SD 40.4611.6 39.8611.6
,10 0 0
10–20 0 3 (3) 0.718
.20 103 (100) 101 (97)
Difference (day15 - baseline) of S. Retinol (mg/dl) after 14 days: mean 6 SD 27.2613.8 27.3614.1 0.979
RBP (mg/dl) on day 15: mean 6 SD 3.8261.08 3.8161.09 0.920
Difference (day 15 - baseline) of RBP (mg/dl) after 14 days: mean 6 SD 2.5861.33 2.5761.35 0.970
Data are n (%) unless otherwise mentioned.
*RBP: Retinol binding protein.
doi:10.1371/journal.pone.0033112.t003
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edematous (13.169.9 mg/dl) and non-edematous (13.268.6 mg/
dl) children. Furthermore, the increases in serum retinol
concentrations after 48 hours as well as on day 15 were similar
in high- and low-dose groups. Similar phenomenon was also
observed in Congolese study [9], where the day 7 serum retinol
was observed comparable (p=NS) in the 3 groups of children who
received high- or low-dose or a placebo and the changes were
0.2060.32, 0.1960.36 and 0.1760.37 mmol/L respectively. In
anaother study
7 done among the apparently well nourished
children (WHZ.21) it was seen that among those with a baseline
serum retinol was ,0.70 mmol/L (equivalent to ,20 mg/dl) the
mean changes in serum retional over 7 days were found similar
between VA suplemented vs. no supplemented group, 0.67 vs.
0.73 mmol/L respectively (p=NS).
Till now the understanding of the molecular mechanisms by
which protein status affects VA dependent functions remains
limited. Compared with healthy children, protein deficient
children and edematous children synthesize less RBP and release
less RBP from the liver, and thus have lower RBP concentrations
[24]. Furthermore, protein deficiency possibly interferes with the
liver storage of VA, as it does in rats [28]. Thus, in protein
deficient children, the response to a massive dose of VA could be
blunt if only checked by biochemical parameters. We do not
believe that the children in our study had received an excess of
VA. Mortality in all three children was in high-dose group in
children but the causes of deaths were very much clear, and
perhaps not related to the doses of VA.
Our findings are consistent with the results of the trial by
Henning et al [29] in Bangladesh, where they found no significant
Table 4. Change in nutritional status by treatment group.
Changes over 2 weeks
(mean ± SD)
High dose vitamin A group
(N=103)
Low dose vitamin A group
(N=104) P Value
Weight (kg)
On day 15 6.7561.44 6.7161.91 0.862
Difference from admission day 0.7460.43 0.6960.51 1.000
Length (cm)
On day 15 69.866.8 69.869.0 0.994
Difference from admission day 0.260.3 0.160.3 0.415
MUAC* (cm)
On day 15 117 (611) 116612 0.510
Difference from admission day 6.064.2 5.265.0 0.298
Head circumference (cm)
On day15 42.562.1 42.262.7 0.368
Difference from admission day 0.3960.37 0.3760.35 0.788
doi:10.1371/journal.pone.0033112.t004
Table 5. Results of exploratory analyses by logistic regression on occurrence of nosocomial morbidities after adjusting the other
co-morbidities/conditions.
Nosocomial morbidity Adjusted OR 95.0% C.I. of adjusted OR P Value
Lower Upper
ALRI{ (all children): variables in model: treatment group, admission retinol, CRP, edema and stunting status
High dose vitamin A group 0.63 0.36 1.09 0.099
Admission retinol ,20 mg/dl 0.70 0.35 1.40 0.312
Admission CRP .10 mg/L 0.74 0.42 1.31 0.295
Edematous children 1.12 0.64 1.94 0.696
Stunted children 2.96 1.47 5.96 0.002
Diarrhea(all children): variables in model: treatment group, admission retinol, CRP, edema and stunting status
High dose vitamin A group 1.25 0.67 2.34 0.483
Admission retinol ,20 mg/dl 1.65 0.68 4.00 0.269
Admission CRP .10 mg/L 0.88 0.46 1.66 0.690
Edematous children 1.21 0.65 2.26 0.541
Stunted children 1.01 0.50 2.01 0.986
CRP: C-reactive protein;
{ALRI: Acute lower respiratory tract infection.
doi:10.1371/journal.pone.0033112.t005
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between children hospitalized with non-cholera acute diarrhea
receiving 200,000 IU VA and children receiving a placebo.
Coutsoudis et al [30] found no significant differences in the
severity of diarrhea episodes at 6-week and 6-month follow-ups of
a group of African children who received 200,000 IU VA on
admission, on days 2 and 8, and at 6 weeks nor in the placebo
group. Most population-based studies of VA that were conducted
outside of hospitals failed to find any significant differences in the
incidence of mild diarrhea (3 or 4 loose stools a day) between VA
supplemented and placebo groups [30–34] In a population-based,
placebo-controlled study in India, weekly low-doses (2500 mg) of
VA for 1 year did not influence the incidence, severity, or duration
of diarrhea or respiratory infections in malnourished children [32].
In Guatemala, high-dose VA supplementation failed to show any
benefit in children with radiographically confirmed ALRIs [7].
On the other hand, in South Africa, children hospitalized with
acute measles recovered more rapidly from pneumonia [30,35,36]
and the frequency and severity of pneumonia episodes were
significantly lower in the VA–supplemented group [30]. Recent
work suggests marked improvements in immune responses after
VA supplementation [37]. Julien et al [38] in a randomized,
double-blind, placebo-controlled clinical trial in Mozambican
children hospitalized with non-measles ALRIs reported beneficial
effect of high-dose of VA. Bangladeshi children with shigellosis
who received VA were less likely to be clinically ill by day 5 than
were children given placebo [39]. In India, children who had pre-
existing VA deficiency and PEM had a significant reduction in the
duration of diarrhea who received high-dose VA supplements [40]
Vietnamese moderately malnourished VA-supplemented children
had a significantly shorter time of hospitalization [41]. Sommer at
al [42] found a decrease in mortality by 34% in 450 villages in
northern Sumatra in preschool children who received 6 monthly
supplementation of 200,000 IU VA compared to the control
children. A more recent study had observed supplementation of
vitamin A to under-five children to be associated with decreased
frequency of diarrhea, ALRI and subsequent malnutrition [43].
WHO recommends single high-dose of VA supplementation for
severely malnourished children [2,3]. The recommendation is
based on studies in communities that showed benefit of the
cheapest intervention, which is quicker to implement into health
programs. Repeated low dosing for longer time often may not
possible in situation where the malnourished children leave the
hospital/treatment centers early due to mothers’/guardians’ other
responsibilities. We conclude that efficacy of daily low-dose (5,000)
VA compared to an additional single high-dose (200,000 IU for 1–
5 years old and 100,000 IU for 6–11 months old) was not observed
to be better in the management of children suffering from SAM
with diarrhea and/or other acute illnesses. Morover the high-dose
VA supplementation in children with SAM did not show any
advers event. Thus single high-dose VA may be given safely to
augment the hepatic reserves and especially where the children
with SAM may leave the hospital/treatment center early.
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